Pfizer, OncoImmune in deal for preclinical CTLA-4 mAb

OncoImmune Inc. (Rockville, Md.) granted Pfizer Inc. (NYSE:PFE) an exclusive option to license rights to ONC-392, a preclinical cytotoxic T-lymphocyte associated protein 4 ( CTLA4; CD152) inhibitor. OncoImmune is eligible to receive $250 million in an upfront payment and milestones, plus tiered royalties up to the low double digits. The biotech declined to provide further details. ...